Allie Strickler

A comparison of anatomic and functional imaging in the assessment of clinical outcomes in patients with Ewing sarcoma has shown that FDG-PET, assessed by PERCIST criteria, was superior in predicting clinical benefits and identifying responses.

The FDA-approved fixed dose of 200 mg of pembrolizumab administered once every 3 weeks yielded durable responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC), according to results from an expansion cohort of the phase Ib KEYNOTE-012 trial.

Findings of a recent population-based, case-control study showed regular screening for cervical cancer was found to be associated with an overall mortality prevention rate of 83%.

A comparison of anatomic and functional imaging in the assessment of clinical outcomes in patients with Ewing sarcoma has shown that FDG-PET, assessed by PERCIST criteria, was superior in predicting clinical benefits and identifying responses, according to a study published in the&nbsp;<em>Journal of Clinical Oncology</em>.<br /> &nbsp;

According to an analysis published in Cancer1, vaginal brachytherapy (VB) has been linked to improved survival in women with stage I endometrioid adenocarcinoma of the uterus.

Apatinib demonstrated an improvement in overall survival by 1.8 months and an acceptable toxicity profile compared to placebo as treatment for advanced gastric cancer.

The use of computed-tomography (CT)-planned high-dose-rate (HDR) intracavitary brachytherapy (BT) demonstrated excellent local control (LC) and survival for patients with stage I/II cervical carcinoma.